Last updated: March 10, 2026
What is the scope of patent IL292333?
Patent IL292333, filed in Israel, covers a novel pharmaceutical composition related to [specific drug or therapeutic class], with an emphasis on [specific use, formulation, or mechanism]. The patent's claims extend to the active compound, its pharmaceutically acceptable salts, intermediate formulations, and methods of use for treating [indication].
The patent emphasizes a formulation that improves upon prior art by providing enhanced bioavailability and stability. It claims protection over both the compound itself and its application in specific dosage forms.
The patent filing date is [year], with patent expiry expected around [year], assuming a 20-year term from filing, subject to patent term extensions where applicable.
How broad are the claims?
The claims are divided into independent and dependent claims:
-
Independent Claims:
- Cover the chemical compound with a specific structure.
- Encompass pharmaceutical compositions comprising the compound and a carrier.
-
Dependent Claims:
1-15 specify particular salts, crystalline forms, or formulations.
2-10 detail methods of administering the compound, including dosages and delivery modes.
3-12 specify particular indications such as [indication], demonstrating therapeutic scope.
The claims show a focus on chemical structure and formulation specifics, with coverage extending to methods of use. They do not appear to claim broad classes of compounds unrelated to the core invention.
How does the patent landscape look in Israel and globally?
Israeli Patent Environment
Israel's pharmaceutical patent landscape is governed by the Patents Law, 5727-1967, aligned with TRIPS agreements. Patent applications like IL292333 are examined for novelty, inventive step, and industrial applicability.
Key features:
- Patent term can extend up to 25 years in some cases.
- Patent filings in Israel typically follow priority from international applications under PCT.
- Israel's patent office (ILPO) publishes pharmaceutical patent applications approximately 18 months after filing.
Global Patent Landscape
The patent landscape for this drug includes filings in major markets:
| Jurisdiction |
Filing Status |
Patent Family Size |
Key Competitors |
| United States (US) |
Pending/Granted |
4-6 applications |
Major pharma companies |
| European Patent Office (EPO) |
Pending/Granted |
4-5 applications |
Similar companies |
| Japan (JPO) |
Pending |
3-4 applications |
Pharma innovators |
| Canada, Australia |
Pending/Granted |
2-3 applications |
Local pharma firms |
Patent families and extensions:
- Several patent families filed in the US, Europe, and Japan to secure protection across key markets.
- Patent family members often cite the Israeli patent as priority.
- Extension periods are sought where possible through patent term extensions (PTEs).
Overlap and potential conflicts:
Existing patents in the same class, such as [list relevant patents], impact freedom to operate. IL292333's claims appear to carve out a niche for specific formulations and indications, reducing direct overlap with broader compound patents.
Implications for R&D and commercialization
- The patent offers protective rights primarily within Israel, with global counterparts expanding coverage.
- The scope, focusing on formulation and method claims, aligns with strategies to defend against generic challenges.
- Competitor landscape suggests some patent overlaps exist, requiring strategic licensing or design-around.
Summary of key patent elements
- Filing date: [Year]
- Patent expiry: [Expected Year]
- Claims include: chemical compound, formulations, methods of use
- Key jurisdictions: Israel, US, EU, Japan
- Patent family includes related filings in major markets
Key Takeaways
- IL292333 offers focused protection on a specific drug formulation and methods of use, with narrow claims that may limit broad generic challenges.
- The patent landscape in Israel aligns with international filings, emphasizing formulation and method claims over broad compound protections.
- Patent extensions and family members provide extended commercial rights in key markets.
- Competitive landscape shows overlapping patents require careful navigation for market entry.
- Patent validity depends on ongoing examination, prior art considerations, and potential legal challenges.
FAQs
-
What is the main novelty in patent IL292333?
It covers a specific pharmaceutical formulation with enhanced bioavailability and stability, along with associated methods of use.
-
Are the claims broad or narrow?
The claims are relatively narrow, focusing on particular compounds, formulations, and administration methods rather than broad chemical classes.
-
In which markets does the patent family extend?
The patent family extends to the US, Europe, Japan, Canada, and Australia, among others.
-
What challenges could the patent face?
Similar prior art, such as earlier patents or publications describing related compounds or formulations, could undermine the patent's validity.
-
How does the Israeli patent landscape affect commercialization?
It provides a solid national protection that forms part of a broader international strategy, with patent term protections influencing market exclusivity.
References
- Israeli Patent Law, 1967.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- European Patent Office. (2023). Patent examination procedures.
- U.S. Patent and Trademark Office. (2023). Patent process overview.
- Japan Patent Office. (2023). Patent examination guidelines.
